NP47827 Multiple Sclerosis Medicines
In plain English
The notice doesn't say
Who holds it now
Last won by Merck Sharp & Dohme UK Ltd and Aventis Pharma Ltd Trading As Sanofi and Crescent Pharma Limited and 23 more in Sep 2026, for £61.8m.
- NP49426a Transition MedicinesMerck Sharp & Dohme UK Ltd, Aventis Pharma Ltd Trading As Sanofi, Crescent Pharma Limited and 23 more £61.8m
- NP90726m Vedolizumab (Entyvio®)Takeda UK Limited
- HIV MedicinesAmarox Limited, Glenmark Pharmaceuticals Europe Ltd, Lupin Healthcare UK Ltd and 11 more £89.9m
What you're up against
- The last two awards went to different firms: this buyer has changed supplier before.
- 35 different firms won this buyer's 3 awards for this kind of work in 2026.
- It last went for £61.8m in 2026.
- The last award named 26 suppliers: it may be a framework, where many firms are chosen.
The notice as published
The Authority seeks to establish a Framework Agreement covering Multiple Sclerosis medicines. The range of medicines under consideration for inclusion in the Framework Agreement are listed below (subject to removal or replacement due to a continually shifting litigation landscape): Glatiramer acetate Interferon beta-1a Teriflunomide Dimethyl fumarate Fingolimod Natalizumab Cladribine Supply of Glatiramer acetate, Interferon beta-1a and Natalizumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published. Supply of cladribine tablets to NHS Scotland. The Authority intends to award this Lot as a ranked multi-supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published. Supply of Fingolimod, Teriflunomide and Dimethyl Fumarate to NHS Scotland. The Authority intends to award this Lot as a ranked multi-supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.